I would agree that at this stage FDA approval of US sites for BetOnMace would be very beneficial for share price. I also think that ph 2/3 orphan indication LAUNCH would also benefit the share price. Both these, along with FIRST RATE analyst coverage, would be solid steps forward in my view. As far as a licensing deal goes, while it would be nice to see more cash come in the door and it would also be additional third party verification of the apabetalone program it is not as big a step forward as the first two items, again JMO. Wrt Koo's point regarding potential dilution, I thought Don had said the next deal would just be for licensing rights only and no equity investment therefore no increase in shareholder base.